T ranscatheter aortic valve implantation (TAVI) procedures have been associated with silent ischemic cerebral embolism as assessed by diffusion-weighted magnetic resonance imaging (DW-MRI) or high-intensity transient signals as assessed by transcranial Doppler.
that are underpowered for the end points studied and, thus, subject to selection biases. Hence, a comprehensive systematic review with a rigorous methodology for quality and credibility assessment is required to better inform decision-making.
We, therefore, conducted a systematic review and metaanalysis to assess silent ischemic lesions and clinically evident cerebrovascular outcomes associated with TAVI procedures performed with and without EPD.
Materials and Methods

Eligibility Criteria
We included studies that evaluated patients who underwent TAVI with and without EPD. Studies included in the meta-analysis had to be parallel group in design, with 1 group having TAVI with EPD and the other having TAVI without EPD. To increase power of the feasibility analysis, we also included single-arm studies that evaluated the feasibility of performing TAVI with EPD. We included studies that evaluated 1 or more of the following outcomes within the 30 days after TAVI: EPD delivery success, stroke or transient ischemic attack, death, new-silent ischemic lesions as assessed by DW-MRI or high-intensity transient signals, neurocognitive function as assessed by Mini-Mental State Examination, Montreal Cognitive Assessment, center for epidemiological studies-depression scale, or National Institutes of Health Stroke Scale. End points, when available, were reported in accordance to Valve Academic Research Consortium-2. 7 Reporting of outcomes had to include either crude events in each group or any risk/odds estimate (relative risk [RR] , hazard ratio, and odds ratio) with 95% confidence intervals (CI).
Search Strategy
We conducted a search of EMBASE, MEDLINE, CINAHL, Web of Science Core Collection, Cochrane Library, and conference abstracts from conception to , using OvidSP (Ovid Technologies). An additional study published after the systematic search was included because of its scientific relevance. The exact search terms used were (transcatheter aortic valve implantation OR TAVI OR transcatheter aortic valve replacement OR TAVR) AND embolic protection device. There was no restriction based on language of study, and both abstracts and unpublished studies presented in conferences were included. A flow diagram is shown in Figure I in the online-only Data Supplement following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). 8 Institutional review board approval and patient consent were not required because of the nature of this study as a systematic review and meta-analysis.
Study Selection
Two reviewers (R. Bagur and K. Solo) independently and in duplicate checked all titles and abstracts for studies that met the inclusion criteria. The full reports of potentially relevant studies were retrieved, and data were independently extracted. Cohen's kappa coefficient was calculated to evaluate agreement between the 2 reviewers at the screening levels. Any discrepancies between reviewers were resolved by discussion after consulting with a third investigator (M.A. Mamas).
Quality Assessment
Risk of bias in the eligible studies was assessed separately for randomized studies using ACROBAT (A Cochrane Collaboration Risk of Bias Tool) 9 and Non-Randomized Studies of Intervention using the ACROBAT-NRSI. 10 The GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) system 11 was used to determine the strength of evidence as high, moderate, low, or very low based on risk of bias, consistency, precision, directness, and publication bias.
Data Analyses
We used RevMan (Review Manager version 5.1.7, Nordic Cochrane Center) to perform random-effects meta-analysis using the MantelHaenszel method to determine pooled RR of EPD compared with non-EPD, with regards to post-TAVI outcomes, for dichotomous data. Standardized mean difference (SMD) was used to combine EPD/non-EPD differences in continuous outcomes across studies and to standardize the results to a uniform scale. Because of insufficient pre/postprocedural data, we excluded case series from quantitative synthesis and assessed them qualitatively. Intention-to-treat analysis was followed whenever possible. When only median and interquartile range were available, we estimated mean and standard deviation using formulas proposed by Wan et al. 12 When only 95% CI was available, normal distribution was assumed when sample size was ≥100, and we calculated standard deviation using the equation proposed by Cochrane Handbook. 13 The I 2 statistic was used to assess the heterogeneity across studies, with an I 2 <25% considered low; I 2 25% to 50%, moderate; and I 2 >75%, high heterogeneity. Cohen kappa agreement scores between the 2 reviewers with respect to title/ abstract and full-text screening were 0.78 and 0.70, respectively, indicating moderate agreement. Subgroup analyses were performed to determine whether the study design or type of bioprosthesis influenced the treatment effect. Two-sided P values of 0.05 were considered statistically significant.
Results
Study Population
A total of 16 studies, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] including 1170 patients (865/305 with/without EPD), fulfilled the inclusion criteria for the qualitative synthesis ( Figure I in the online-only Data Supplement). The mean age was 81.7 years, and 50.2% were female in 14 studies that reported both age and sex. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [26] [27] [28] [29] The presence of baseline atrial fibrillation was reported in 9 studies, [17] [18] [19] 21, 22, 26, 27, 29 with a prevalence of 31.6% (285/902 patients). Previous stroke was reported in 14 studies, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [26] [27] [28] [29] with a prevalence of 10.8% (111/1028 patients). More details can be appreciated in the Results and Tables I and II in the online-only Data Supplement).
Risk of Bias and Quality of Evidence
A complete description can be appreciated in the onlineonly Data Supplement and Table III in the online-only Data Supplement. The quality of overall evidence was low-to-very low, with the main limitation being serious risk of bias and imprecision. The GRADE summary of certainty in outcomes is presented in Table IV in the online-only Data Supplement.
Thirty-Day Outcomes
Device type, access site, procedure-related outcomes, and follow-up assessment for all included studies reporting crude rate of events are summarized in Table V in the online-only Data Supplement. The EPD delivery success rate was reported in all studies [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] and was achieved in 94.5% (804/851) of patients, ranging from 64% to 100%. All-cause mortality was reported in 9 studies [17] [18] [19] [20] [21] [22] [27] [28] [29] 
Association of EPD Versus No EPD With Silent Ischemic Lesions: DW-MRI Assessment
Study Design and Type of Valve Subgroup Analyses
In the subgroup analyses by study design, randomized trials as compared with nonrandomized studies, the use of EPD did not significantly reduce the incidence of stroke (RR, 0. 29 that provided data on balloon-expandable Edwards Sapien-XT and Sapien-3 valves, separately, the EPD arm showed no apparent benefit in terms of number of lesions and total volume of lesions when the Sapien-3 only (excluding Sapien-XT) was computed into the meta-analyses ( Figure IV in the online-only Data Supplement). 
Impact of EPD Versus No EPD on Neurocognitive Function
The assessment of neurocognitive function for all included studies is detailed in Table 2 . In comparative studies, patients were assessed by the Montreal Cognitive Assessment before and after TAVI in 3 studies, 17, 22, 27 and the proportion of patients with EPD showing worsening neurocognitive function ranged from 10.7% to 27.3% and from 22.7% to 33.3% in patients without EPD. Three studies 22, 27, 28 used the National Institutes of Health Stroke Scale, and the proportion of patients with EPD showing worsening neurocognitive function ranged from 0% to 17.9% and from 4.5% to 22.5% in patients without EPD. The Mini-Mental State Examination was used in 1 study 17 and did not show differences between EPD versus without EPD strategies.
Discussion
Imaging studies reported that silent ischemic embolic lesions commonly occurred in patients undergoing TAVI, despite the fact of using EPD. Our meta-analysis suggests that the use of EPD may be associated with smaller volume of ischemic lesions. Yet, EPD may not necessarily lead to reductions in the number of new-single, multiple, and total number of lesions and may be associated with a numerically increased risk of high-intensity transient signals in certain studies (online-only Data Supplement). No significant differences were found between patients undergoing TAVI either with or without EPD with respect to hard end points, such us clinically evident stroke or mortality. Failure to deliver the EPD occurred in ≈5% of patients.
Silent and Clinically Evident Ischemic Cerebrovascular Insults After Aortic Valve Procedures
Previous studies have shown an incidence of new-silent cerebral ischemic embolic lesions after TAVI up to 84%, whereas new persistent clinical neurological impairment was ≈3% to 6%. [1] [2] [3] [4] [5] Silent lesions affected the 2 cerebral hemispheres and circulation territories in most of the patients. [1] [2] [3] [4] [5] Importantly, when DW-MRI was performed at follow-up, investigators agreed with the fact that ischemic lesions tended to disappear shortly after the TAVI procedure. 1, 2, 17, 28 Notably, looking at surgical aortic valve replacement populations, new cerebral ischemic lesions were reported up tosurgical aortic valve replacement populations, new cerebral ischemic lesions were reported up to 60% of patients 1, [31] [32] [33] [34] [35] ; lesions were often multiple, mostly clinically silent and were found to be of a smaller volume when compared with TAVI. 1 Messé et al 35 detected silent cerebral infarctions in 61% of the patients undergoing surgical aortic valve replacement; however, the authors reported the highest (17%) rate of stroke to date. This study highlights the importance of performing a systemic and specialized neurological assessment after cardiac interventions. 35 Hereof, when routine neurological and DW-MRI assessment was performed in a TAVI population, clinically apparent neurological deficits were matched with positive DW-MRI ischemic lesions in ≈15% of controls in the DEFLECT-III trial (A Prospective, Randomized Evaluation of the TriGuard HDH Embolic Deflection Device During TAVI). 22 It is worth to be mentioned that the available data from observational studies used 1.5-T MRI scanners. In this regard, the 3 randomized EPD studies, the MISTRAL-C (MRI Investigation in TAVI With Claret), 27 CLEAN-TAVI (Claret Embolic Protection and TAVI), 28 and SENTINEL 29 used 3-T MRI scanners, although 11 patients in the CLEAN-TAVI underwent MRI in a 1.5-T scanner because of pacemaker dependency. 28 Hence, one may think that tiny emboli might have been missed with a 1.5-T MRI scanner; on the other hand, the use of a 3-T MRI scanner, which has a higher sensitivity, may have overestimated the lesions. Therefore, the interpretation of the current results might be difficult to correlate with the daily basis clinical practice.
Type of TAVI Device and Its Impact on Silent Ischemic Embolism
The number and volume of ischemic lesions tended to be greater with the self-expanding device.
22,27-29 Lansky et al 22 showed that the freedom from ischemic lesions, as assessed by DW-MRI, among patients undergoing TAVI with EPD using the balloon-expandable valve was ≈30%, whereas all patients undergoing TAVI with the self-expanding CoreValve had ischemic lesions, despite the fact of using the TriGuard HDH (Keystone Heart, Caesarea, Israel) embolic deflection device that, indeed, covers all brain territories. Moreover, these subjects accounted for the largest lesion volumes in the EPD group. 22 This finding is in line with that of the CLEAN-TAVI 28 trial showing that almost 100% of patients exhibited new ischemic lesions in the EPD arm. The SENTINEL trial 29 further supports that self-expanding devices were associated with larger lesion volume as compared with the balloon-expandable Edwards Sapien-XT and Sapien-3 bioprostheses, and this is taking into consideration that the trial mainly used the new-generation selfexpanding Medtronic Evolut-R device. 29 Furthermore, the subgroup of patients receiving the new-generation balloonexpandable Sapien-3 device appeared to obtain a less protective effect from the EPD ( Figure IV in the online-only Data Supplement).
Silent Ischemic Lesions and Neurocognitive Function After TAVI
There is a clear discrepancy between the incidence of new ischemic lesions after TAVI and the rates of clinically apparent neurological impairment. Previous studies showed that the occurrence of silent ischemic embolism was not associated with a measurable pre-/post-TAVI impairment in neurocognitive function. 5 did not find association between the number of cerebral infarcts and the reported mental health and quality-oflife assessments. 5 Furthermore, 2 studies showed a significant improvement in Mini-Mental State Examination scores 3 months after TAVI. 6, 36 The PROTAVI-C study (Prospective Randomized Outcome Study in Patients Undergoing TAVI to Examine Cerebral Ischemia and Bleeding Complications) 17 showed no differences with and without EPD in pre/postprocedural neurological evaluation using the National Institutes of Health Stroke Scale scale, nor cognitive assessment with the Mini-Mental State Examination. The cognitive status evaluated by the Montreal Cognitive Assessment showed significant improvement at 30 days compared with baseline in the EPD arm, but no differences over time without EPD. 17 In this regard, the DEFLECT-III trial 22 showed that after adjusting for age, the mean Montreal Cognitive Assessment score improved from baseline to discharge and 30 days in the EPD group; however, in the control group, the mean score declined from baseline to discharge but rebounded to approximately baseline levels at 30 days. Therefore, no statistical significance was observed between groups of treatment at 30-day follow-up. 22 The SENTINEL trial 29 used a comprehensive neurocognitive assessment tailored for TAVI patients and designed to evaluate 7 domains of neurocognitive function, and the use of EPD did not show any change in neurocognitive function.
In terms of long-term follow-up, Ghanem et al 37 reported that 91% of patients presented preserved cognitive performance throughout the first 2 years after TAVI. Notably, the age of the patient, but neither the absence of silent cerebral embolism nor the use of EPD, affected cognitive trajectory in this study. 37 Finally, one should bear in mind the present concern about silent ischemic lesions and its potential negative (or not) impact on neurocognitive function once TAVI will be extended to younger and less sick patients exhibiting a longer life expectancy. Thus, further investigations are needed to improve the identification of patients at high risk for embolization, such as those with extensive atherosclerosis/complex aortic atheroma, porcelain aorta, carotid disease, or left atrial appendage thrombus.
5,38-40
Limitations
The main limitation of this research lies with the small number of studies, patients and events informing each outcome, and the high rate of loss to follow-up in most of studies. Patientlevel data were not available, precluding, therefore, a more robust adjustment for any differences in baseline data, such as atrial fibrillation, previous stroke, peripheral vascular disease, or pooling relevant outcomes (ie, stroke and death) for a combined end point. Also, because of insufficient data, we were not able to obtain summary mean estimates of pre/postprocedural values for neurocognitive end points. Nevertheless, in studies where clinical, demographics, and anatomic features were reported, populations were well-balanced in terms of baseline characteristics across the study groups.
